Page 14 - Tim Walbert News Today

Horizon Therapeutics to Expand Pipeline, R&D with $3B Viela Bio Acquisition Horizon Therapeutics has agreed to acquire Viela Bio for approximately $3.05 billion, the companies said, in a deal designed to strengthen the buyers pipeline and R&D. [Viela Bio] February 1, 2021 Horizon Therapeutics has agreed to acquire Viela Bio for approximately $3.05 billion, the companies said, in a deal designed to strengthen the buyers pipeline and R&D. [Viela Bio] Share Horizon Therapeutics has agreed to acqu...

Horizon Therapeutics plc (NASDAQ: HZNP) and Viela Bio, Inc. (NASDAQ: VIE) have entered into a definitive agreement where Horizon will acquire all issues and outstanding shares of Vielo Bio common stock for USD 53 per share in cash or a fully diluted equity value of USD 3.05 Billion.  The transaction is expected to close by the end of the first quarter of 2021.  “This acquisition represents a significant step forward in advancing our strategy – to expand our pipeline in order to accelerat...

Source: Streetwise Reports  (2/1/21) Shares of Viela Bio traded higher after it was announced that the company entered into a definitive agreement to be acquired by Horizon Therapeutics for $53.00 per share. Prior to the opening of U.S. market for trading today, clinical-stage biotechnology firm Viela Bio Inc. (VIE:NASDAQ), which is focused on pioneering treatments for autoimmune and severe inflammatory diseases and Horizon Therapeutics Plc (HZNP:NASDAQ), announced that t...

Horizon Therapeutics plc Announces Short-Term TEPEZZA (teprotumumab-trbw) Supply Disruption Due to Government-Mandated (Operation Warp Speed) COVID-19 Vaccine Production IMPORTANT SAFETY INFORMATION Warnings and Precautions Infusion Reactions: TEPEZZA may cause infusion reactions. Infusion reactions have been reported in approximately 4% of patients treated with TEPEZZA. Reported infusion reactions have usually been mild or moderate in severity. Signs and symptoms may include transient increase...